Document is current

Documents that mention this clinical trial

Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study
https://doi.org/10.1136/annrheumdis-2018-213271

Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis
https://doi.org/10.1136/rmdopen-2019-000898

Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies
https://doi.org/10.1136/annrheumdis-2017-212461

Efficacy of Long-Term Treatment with Once-Daily Baricitinib 2 mg in Patients with Active Rheumatoid Arthritis: Post Hoc Analysis of Two 24-Week, Phase III, Randomized, Controlled Studies and One Long-Term Extension Study
https://doi.org/10.1007/s40744-021-00317-9

Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database
https://doi.org/10.1136/annrheumdis-2021-221276

Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis
https://doi.org/10.1136/rmdopen-2019-001095

Efficacy and safety data based on historical or pre-existing conditions at baseline for patients with active rheumatoid arthritis who were treated with baricitinib
https://doi.org/10.1136/annrheumdis-2018-214261

Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis
https://doi.org/10.1136/annrheumdis-2018-214529

Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
https://doi.org/10.1136/annrheumdis-2016-210094

Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs
https://doi.org/10.1136/rmdopen-2018-000662